PRAC continues to closely review Comirnaty (Pfizer) and Moderna COVID-19 vaccines for thromboembolic events

PRAC considers that the current evidence does not suggest a causal relation since only a few cases have been reported and they do not seem to present the specific clinical pattern observed with Astra Zeneca and Janssen COVID-19 vaccines.

SPS commentary:

PRAC has concluded that benefits of the Janssen COVID-19 vaccine outweigh the risks of side effects but ‘thrombosis with thrombocytopenia syndrome’ will be added as an ‘important identified risk’ which requires further investigation should this occur within three weeks of vaccination.


European Medicines Agency